Abstract
A new method employing the principle of superimposition was developed to aid in the formulation of sustained-release dosage forms. Independently absorbed components of a product, e.g., waxed pellets for an oral capsule, are administered separately and their plasma level-time profiles determined. Using a trial and error procedure, the ratios of pellets are varied to obtain a desired plasma level-time profile. The use of (1) time averaged plasma concentration-time data, (2) amount remaining to be absorbed (excreted) plots, and (3) cumulative amount absorbed (excreted) plots were all shown to be inappropriate for pharmacokinetic analyses in general, and evaluation of sustained-release products in particular. It was recommended that raw plasma concentration-time data be made available for sustained-released products, and that individual rate of absorption plots be used to assess absorption kinetics. It was concluded that much of the sustained-release pharmacokinetic data presently in the literature have been presented in such a manner, e.g. averaged data, as to be of limited value.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Boxenbaum, H. (1982) Drug Develop. Indust. Pharm. 8, 1–25.
Rowland, M., Beckett, A. H. (1964) J. Pharm. Pharmacol. 16, 156 T–162 T.
Robinson, J. R., Eriksen, S. P. (1966) J. Pharm. Sci. 55, 1254–1263.
Ashby, R. (1952) Design for a Brain, Chapman & Hall, London.
Gibaldi, M., Perrier, D. (1982) Pharmacokinetics, 2nd ed., pp. 188–198, 451–457, Marcel Dekker, Inc., N. Y.
Theeuwes, F., Bayne, W. (1977) J. Pharm. Sci. 66, 1388–1392.
Adair, D. Personal communication.
Levy, G., Jusko, W. J. (1966) J. Pharm. Sci. 55, 285–289.
Boxenbaum, H. G., Jodhka, G. S., Ferguson, A. C., Riegelman, S., MacGregor, T. R. (1974) J. Pharmacokin. Biopharm. 2, 211–237.
Wagner, J. G. (1975) Fundamentals of Clinical Pharmacokinetics, pp. 136–145, Drug Intelligence Publications, Inc., Hamilton, Ill.
Rowland, M., Tucker, G. (1980) J. Pharmacokin. Biopharm. 8, 497–507.
Loo, J. C. K., Riegelman, S. (1968) J. Pharm. Sci. 57, 918–928.
Till, A. E., Benet, L. Z., Kwan, K. C. (1974) J. Pharmacokin. Biopharm. 2, 525–544.
Till, A. E., Benet, L. Z., Kwan, K. C. (1975) J. Pharmacokin. Biopharm. 3, 291.
Boxenbaum, H. G., Kaplan, S. A. (1975) J. Pharmacokin. Biopharm. 3, 257–264.
Straughn, A. B., North, L. J. Presented at the 14th annual midyear clinical meeting, American Society of Hospital Pharmacists, Dec. 2–6, 1979, Las Vegas, Nevada (Data on file, Key Pharmaceuticals, Inc., Miami, Fla.).
Daniel, C., Wood, F. S. (1971) Fitting Equations to Data, Wiley-Interscience, N. Y.
Boxenbaum, H. G., Riegelman, S., Elashoff, R. M. (1974) J. Pharmacokin. Biopharm. 2, 123–148.
Wagner, J. G. (1963) J. Pharm. Sci. 52, 1097–1101.
Martin, B. K. (1967) Brit. J. Pharmacol. Chemother. 29, 181–193.
Simons, K. J., Frith, E. M., Simons, F. E. R. (1982) J. Pharm. Sci. 71, 505–511.
Tang-Liu, D. D., Williams, R. L., Riegelman, S. (1982) Clin. Pharmacol. Therap. 31, 358–369.
Wagner, J., Nelson, E. (1964) J. Pharm. Sci. 53, 1392–1403.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Boxenbaum, H. Pharmacokinetic Determinants in the Design and Evaluation of Sustained-Release Dosage Forms. Pharm Res 1, 82–88 (1984). https://doi.org/10.1023/A:1016355431740
Issue Date:
DOI: https://doi.org/10.1023/A:1016355431740